JPMorgan Starts Coherus Biosciences (CHRS) at Overweight
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $2.18 --0%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Join SI Premium – FREE
JPMorgan initiated coverage on Coherus Biosciences (NASDAQ: CHRS) with an Overweight rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Coherus Biosciences click here. For more ratings news on Coherus Biosciences click here.
Shares of Coherus Biosciences closed at $13.37 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cantor Fitzgerald Starts Incyte (INCY) at Neutral, 'JAK-ing Up Its Pipeline In Advance of a Major Patent Cliff'
- Canaccord Genuity Starts Pan African Resources PLC (PAF:LN) at Buy
- BofA Securities Reinstates Gujarat Gas Ltd (GUJGA:IN) at Underperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
